BIOHIT OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2 EUR | -0.99% |
|
+1.01% | +6.10% |
| 06-14 | Finland's Biohit Names Chief Technology Officer | MT |
| 04-15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 47% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
Ratings chart - Surperformance
Sector: Office Equipment
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +6.10% | 32.42M | - | ||
| +0.10% | 7.29B | B- | ||
| -10.19% | 4.42B | B | ||
| +1.75% | 3.19B | - | ||
| +2.94% | 2.04B | - | ||
| -31.17% | 1.05B | - | ||
| +5.30% | 911M | - | ||
| -50.14% | 787M | - | ||
| -24.23% | 673M | - | - | |
| -32.11% | 665M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIOBV Stock
- Ratings Biohit Oyj
